TRPV1 antagonist JNJ-39439335 (mavatrep) demonstrates proof of pharmacology in healthy men: a first-in-human, double-blind, placebo-controlled, randomized, sequential group study

This double-blind, randomized, placebo-controlled, sequential group, phase 1 study was designed to assess in healthy men, the safety, tolerability, pharmacokinetics, and translational pharmacodynamics of JNJ-39439335 (mavatrep), a transient receptor potential vanilloid subtype 1 antagonist; it was p...

Descripción completa

Detalles Bibliográficos
Autores principales: Manitpisitkul, Prasarn, Brandt, Michael, Flores, Christopher M., Kenigs, Velga, Moyer, John A., Romano, Gary, Shalayda, Kevin, Mayorga, Arthur J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer 2016
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5741288/
https://www.ncbi.nlm.nih.gov/pubmed/29392196
http://dx.doi.org/10.1097/PR9.0000000000000576

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5741288/
https://www.ncbi.nlm.nih.gov/pubmed/29392196
http://dx.doi.org/10.1097/PR9.0000000000000576

Ejemplares similares